Latest Regulatory News

New World Resources has secured a critical federal permitting milestone for its Antler Copper Project, setting a clear path to full approval within 12 months and construction commencement in H2 2025.

Atlas Arteria reveals it will face a significant temporary supplemental tax under France’s new 2025 Finance Law, impacting its APRR Group operations with payments due late next year.

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.

Nick Scali Limited has announced a fully franked ordinary dividend of AUD 0.30 per share for the six months ending December 2024, signaling steady shareholder returns.

News Corporation reported a robust half-year performance with revenues up 4% to $4.33 billion and net income soaring 80% to $334 million, while advancing its strategic pivot through the planned sale of Foxtel.

Neuren Pharmaceuticals has secured a pivotal FDA Type C Meeting to discuss primary efficacy endpoints for its Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, advancing its rare disease drug development.

Shekel Brainweigh Ltd has requested an immediate suspension from ASX quotation as it moves towards removal from the official ASX list, raising questions about the company’s future.

SEQ Hospitality Group has formally withdrawn its off-market takeover bid for Eumundi Group following shareholder and court approval of a competing scheme of arrangement. This move effectively ends the takeover offer and confirms the scheme as the path forward for Eumundi shareholders.

Polymetals Resources Ltd has temporarily paused trading of its securities, signaling an imminent announcement that could reshape investor expectations.

Actinogen Medical has published a peer-reviewed article confirming the efficacy of a 10 mg daily dose of Xanamem for treating neurological conditions, reinforcing its ongoing clinical trials in Alzheimer's and depression.

Micro-X Ltd has announced a $6 million capital raising alongside a $2.4 million strategic investment from Billion Prima, underpinning its pivot towards medical imaging and cashflow stability.

JPMorgan Asset Management has announced the final cash distributions for February 2025 across several of its active ETFs, providing investors with key dates and reinvestment options.